

ImmunogenX Publishes in Celiac Disease Journal

Team advances key understanding of the magnitude of symptoms caused by gluten

The symptomatic response to gluten ingestion in celiac disease (CD) patients is a topic of great importance but with little quantitative understanding. ImmunogenX is pleased to announce a publication from its team that applies a new algorithm to recent clinical data to further elucidate on this relationship [J.A. Syage and P.T. Lavin, “Modeling Symptom Severity and Estimated Gluten Ingestion in Celiac Disease Patients on a Gluten-Free Diet.” *International Journal of Celiac Disease*, vol. 8, no. 3 (2020): 85-89. doi: 10.12691/ijcd-8-3-3].

The novel algorithm used baseline and placebo data from the CeliAction[®] trial (ALV003-1221, NCT01917630). The symptoms evaluated were abdominal pain, bloating and tiredness. The study found that episodic gluten ingestion of 200-400 mg can trigger each of these symptoms (mild or greater severity) and which occur multiple times per week in generally symptomatic patients. Moderate and severe symptoms are triggered by gluten ingestion of about 0.7-1.4 g and 1.2-2.6 g of gluten, respectively and occur about 4 times per month and 1-2 times per month, respectively. The range of gluten ingestion is due to different responses for each symptom with abdominal pain being less frequent and requiring more gluten and tiredness being more frequent and requiring less gluten for comparable severity. Certain assumptions to the algorithm combined with the variability among CD patients limits making further definitive statements. This work suggests avenues for new studies to better refine the understanding of the relationship of episodic gluten ingestion and symptom severity.

Jennifer A. Sealey Voyksner, PhD and CSO of ImmunogenX remarks “ImmunogenX continues to establish its leadership in celiac disease clinical research in developing the front runner therapeutic candidate Latiglutenase and in advancing the scientific understanding of the disease itself. Through excellence by its clinical and scientific team, we believe we will provide great benefit to celiac patients in their battle with the disease.”

About ImmunogenX

ImmunogenX (a subsidiary of Immunogenics LLC) is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing Latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCel[™]) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. For food safety, ImmunogenX is pioneering advanced mass spectrometry methods to identify and measure physiologically relevant gluten peptide sequences found in wheat, barley, and rye.

www.immunogenx.com

For further information please contact

Matthew Dickason, MBA
Chief Operating Officer
949 679-0900
mdickason@immunogenx.com